کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
5546533 | 1555978 | 2017 | 7 صفحه PDF | دانلود رایگان |
Arsenic trioxide (ATO) is used as a chemotherapeutic agent for the treatment of acute promyelocytic leukemia. However, increasing drug resistance is reducing its efficacy. Therefore, a better understanding of ATO resistance mechanism is required. In this study, we established an ATO-resistant human epidermoid carcinoma cell line, KB/ATO, from its parental KB-3-1 cells. In addition to ATO, KB/ATO cells also exhibited cross-resistance to other anticancer drugs such as cisplatin, antimony potassium tartrate, and 6-mercaptopurine. The arsenic accumulation in KB/ATO cells was significantly lower than that in KB-3-1 cells. Further analysis indicated that neither application of P-glycoprotein inhibitor, breast cancer resistant protein (BCRP) inhibitor, or multidrug resistance protein 1 (MRP1) inhibitor could eliminate ATO resistance. We found that the expression level of ABCB6 was increased in KB/ATO cells. In conclusion, ABCB6 could be an important factor for ATO resistance in KB/ATO cells. The ABCB6 level may serve as a predictive biomarker for the effectiveness of ATO therapy.
An ATO-resistant human epidermoid carcinoma cell line, KB/ATO, was established from its parental KB-3-1 cells. The arsenic accumulation in KB/ATO cells was significantly lower than that in KB-3-1 cells and the expression level of ABCB6 was increased. The upregulated ABCB6 may be important for ATO resistance in KB/ATO cells.138
Journal: Acta Pharmaceutica Sinica B - Volume 7, Issue 5, September 2017, Pages 564-570